 Solid tumors create an unfavorable microenvironment that depletes T cells of critical nutrients and amino acids, drives T cell dysfunction, and inhibits the effectiveness of cellular therapies, and our BOXR platform was specifically developed to discover novel transgenes that can be co-expressed with chimeric-targeting receptors to improve T cell functionality in the solid tumor microenvironment, said Seth Ettenberg, Ph.D., Chief Scientific Officer of Unum. At this years SITC, we present preclinical data on the first product candidate from our BOXR platform, BOXR1030, which contains the GOT2 transgene. 